AstraZeneca PLC - American Depositary Shares (AZN)
67.57
+0.27 (0.40%)
NASDAQ · Last Trade: May 10th, 1:28 PM EDT
Detailed Quote
Previous Close
67.30
Open
68.04
Bid
67.45
Ask
67.75
Day's Range
67.52 - 68.63
52 Week Range
61.24 - 87.68
Volume
6,216,036
Market Cap
-
PE Ratio (TTM)
-
EPS (TTM)
-
Dividend & Yield
2.100 (3.11%)
1 Month Average Volume
5,862,392
Chart
About AstraZeneca PLC - American Depositary Shares (AZN)
AstraZeneca is a global biopharmaceutical company that focuses on the research, development, and manufacturing of a wide range of prescription medications. The company's primary areas of expertise include oncology, respiratory diseases, cardiovascular systems, and immunology, with a commitment to advancing innovative treatments that improve patient outcomes. AstraZeneca collaborates with healthcare professionals, researchers, and academic institutions to drive scientific advancements and ensure that their therapies reach those in need. Through its extensive portfolio, the company aims to address some of the world’s most pressing health challenges while maintaining a strong emphasis on sustainability and corporate responsibility. Read More
Positive high-level results from the POTOMAC Phase III trial showed one year of treatment with AstraZeneca’s IMFINZI® (durvalumab) plus standard-of-care BCG induction and maintenance therapy demonstrated a statistically significant and clinically meaningful improvement in disease-free survival (DFS) for patients with high-risk non-muscle-invasive bladder cancer (NMIBC) compared to BCG induction and maintenance therapy alone.
Pharma ETFs closely watched as Trump's drug policies stir market volatility. Funds offer sector exposure but differ in risk levels and growth potential.
Tempus AI is gaining traction and on track for profits this year; high short interest and rising institutional activity point to significant upside potential.
Positive high-level results from the DESTINY-Breast11 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by paclitaxel, trastuzumab and pertuzumab (THP) demonstrated a statistically significant and clinically meaningful improvement in pathologic complete response (pCR) rate versus standard of care (dose-dense doxorubicin and cyclophosphamide followed by THP [ddAC-THP]) when used in the neoadjuvant setting (before surgery) in patients with high-risk, locally advanced HER2-positive early-stage breast cancer. Pathologic complete response is defined as no evidence of invasive cancer cells in the removed breast tissue and lymph nodes following treatment.
The biggest strategic highlight for Tempus AI Inc. (NASDAQ: TEM) during the first quarter was a multi-million dollar deal to build "the world's largest foundation model for oncology."
The approval is based on positive results from a phase 3 trial, which demonstrated that Calquence plus bendamustine and rituximab reduced the risk of disease progression or death by 27% compared to standard-of-care chemoimmunotherapy.
AstraZeneca said on Friday that the full results from the two trials will be shared with regulatory authorities and presented at an upcoming medical meeting.
Positive high-level results from the Phase III KALOS and LOGOS trials in patients with uncontrolled asthma showed that AstraZeneca’s fixed-dose triple-combination therapy BREZTRI AEROSPHERE (budesonide/glycopyrronium/formoterol fumarate or BGF (320/28.8/9.6μg)) met all primary endpoints, demonstrating a statistically significant and clinically meaningful improvement in lung function compared with dual-combination inhaled corticosteroid/long-acting beta2-agonist (ICS/LABA) medicines.
AstraZeneca posts Q1 revenue of $13.59 billion and a strong EPADS beat; oncology leads growth as China's tax probe and halts the Truqap trial in prostate cancer.
U.S. stock futures are trading flat on Tuesday early-morning, keeping with the broad index averages on Monday, as markets await clarity and more earnings reports to come in over the course of this week.
Biopharma stocks rally along with many of our SMID cap trades. The market situation with pharmaceuticals is even more complicated because we started off with legislation (the IRA) trying to curb rising drug and healthcare costs.
Tempus AI Inc (NASDAQ:TEM) shares are surging Wednesday after the company announced a multi-year collaboration with AstraZeneca PLC (NASDAQ:AZN) and Pathos AI.
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.
Positive high-level results from a planned interim analysis of the DESTINY-Breast09 Phase III trial showed ENHERTU® (fam-trastuzumab deruxtecan-nxki) in combination with pertuzumab demonstrated a highly statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to a taxane, trastuzumab and pertuzumab (THP) as a 1st-line treatment for patients with HER2-positive metastatic breast cancer.
